Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Vaccines. 2008 Feb;7(1):25-31. doi: 10.1586/14760584.7.1.25.

Oral adenoviral-based vaccines: historical perspective and future opportunity.

Author information

1
Vaxart, Inc., 600 Townsend St, Suite 120E, San Francisco, CA 94103, USA. stucker@vaxart.com

Abstract

Adenoviral vaccines delivered orally have been used for decades to prevent respiratory illness, but are now being seriously explored again as a platform technology to make vaccines against a variety of pathogens. Years of use in military populations as a preventative measure for adenoviral infection have demonstrated the safety of oral administration of adenovirus. The advantages of using this approach as a platform technology for vaccines include rapid development and distribution, as well as ease of administration. Recent discoveries may allow this platform approach to reach the clinic within a few years.

PMID:
18251691
DOI:
10.1586/14760584.7.1.25
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center